Niagen Bioscience, Inc. (NAGE) SEC Filings & Earnings Calls
EquiReason read 13 Niagen Bioscience, Inc. SEC filings in the last 12 months. Latest: 10-Q on 2026-08-04 — Niagen Bioscience reported Q2 2026 net sales of $29.8M (-4% YoY) and net income of $1.0M (-73% YoY), with consumer product growth offset by ingredient sales decline due to NMN comp.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 192.3M
- P/E TTM
- 13.5
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
4 Aug 202610-QNiagen Bioscience reported Q2 2026 net sales of $29.8M (-4% YoY) and net income of $1.0M (-73% YoY), with consumer product growth offset by ingredient sales decline due to NMN competition and margin pressure.earningsopen
Figures in the filing · each found in the filing text
| Net sales · Q2-2026 | $30M | -4% y/y |
| Net income · Q2-2026 | $963000.00 | -73% y/y |
| Consumer Products net sales · Consumer Products · Q2-2026 | $24M | +6% y/y |
| Ingredients net sales · Ingredients · Q2-2026 | $5M | -29% y/y |
| Operating cash flow · H1-2026 | $2M | -82% y/y |
Risks flagged
NMN competition eroding ingredient business
“In September 2025, the FDA determined that nicotinamide mononucleotide (NMN) may be lawfully marketed as a dietary ingredient. The availability of NMN products as dietary supplements has increased competition... We have experienced the impacts of this competition in our ingredient business, including on our financial results, since the September 2025 FDA dec” · word for word
Dependence on single supplier for NRC
“We rely on a single supplier, W.R. Grace, for NRC and a limited number of third-party suppliers for the raw materials required to produce our products.” · word for word
History of operating losses
“From inception through June 30, 2026, we have incurred aggregate losses of approximately $157.2 million.” · word for word
4 Aug 20268-K · 2.02, 7.01Net Sales $30M; Tru Niagen Net Sales $24M; Gross Margin 64.8; Guidance: E-commerce growth 10-15% YoYearningsopen
Figures in the filing · each found in the filing text
| Net Sales · Q2-2026 | $30M | |
| Tru Niagen Net Sales · Tru Niagen · Q2-2026 | $24M | |
| Gross Margin · Q2-2026 | 64.8% | |
| Net Income · Q2-2026 | $1M | |
| Adjusted EBITDA · Q2-2026 | $3M | |
| Diluted EPS · Q2-2026 | $0.01 | |
| Cash and Cash Equivalents · Q2-2026 | $67M | |
| Operating Cash Flow (YTD) · H1-2026 | $2M |
Guidance
E-commerce growth 10-15% YoY
Reaffirmed e-commerce growth guidance; expects ingredient business to be lower; strategic investments to increase OpEx.
Risks flagged
Ingredient business expected to be lower YoY due to competitive market.
“The ingredient business is expected to be lower than the prior year as some of our commercial partners continue to face a more competitive market.” · word for word
Operating expenses expected to increase as company invests in strategic priorities.
“expects operating expenses to increase as it invests across commercial, research and administrative functions to support these strategic priorities.” · word for word
6 May 202610-QNet Sales $31M (+3% y/y); Consumer Products Net Sales $22M (+4% y/y); Ingredients Net Sales $9M (+5% y/y)open
Figures in the filing · each found in the filing text
| Net Sales · Q1-2026 | $31M | +3% y/y |
| Consumer Products Net Sales · Consumer Products · Q1-2026 | $22M | +4% y/y |
| Ingredients Net Sales · Ingredients · Q1-2026 | $9M | +5% y/y |
| Net Income · Q1-2026 | $6M | +25% y/y |
| Cash and Cash Equivalents · 2026-03-31 | $67M | |
| Gain on Sale of Operating Segment · Q1-2026 | $5M |
Risks flagged
Customer concentration risk
“Sales to A.S. Watson's were lower by $2.4 million compared to the prior year, reflecting variability in ordering patterns.” · word for word
Operating cash flow volatility
“Net cash used in operating activities was approximately $1.2 million, compared to net cash provided by operating activities of approximately $7.9 million for the same period in 2025.” · word for word
Inventory build risk
“Inventory increased, resulting in a $3.6 million use of cash during the current period.” · word for word
6 May 20268-K · 2.02, 7.01Net sales increased 3% to $31.5M; gross margin improved to 63.5%; net income $6.3M vs $5.1M prior year; updated FY2026 outlook with improved G&A expense guidance.earningsopen
Figures in the filing · each found in the filing text
| Net sales · Q1-2026 | $32M | +3% y/y |
| Gross margin · Q1-2026 | 63.5% | |
| Net income · Q1-2026 | $6M | +24% y/y |
| Adjusted EBITDA · Q1-2026 | $4M | -22% y/y |
| Cash and cash equivalents · Q1-2026 | $67M | |
| Operating cash flow · Q1-2026 | $-1M | |
| Basic EPS · Q1-2026 | $0.08 | +14% y/y |
| Diluted EPS · Q1-2026 | $0.07 | +17% y/y |
| Tru Niagen net sales · Tru Niagen · Q1-2026 | $22M |
Guidance
FY2026 net sales growth 10-15% YoY (ex-divested); G&A expense improved to $3-4M from $4-5M; S&M increasing as % of sales (previously stable)
FY2026 guidance updated: net sales growth 10-15% YoY (ex-divested), G&A expense improved to $3-4M from $4-5M, S&M increasing as % of sales (previously stable).
Risks flagged
Operating cash flow negative due to inventory and receivable build
“Used $1.2 million in operating cash flow during the quarter, driven by increased inventory levels and timing of receivables” · word for word
Sales & marketing spend increasing as % of sales, pressuring margins
“Sales & marketing: Increasing in absolute dollars and as a percentage of sales” · word for word
29 Apr 2026DEF 14AProxy statement for 2026 annual meeting, disclosing executive compensation, governance, and shareholder voting matters.open
Figures in the filing · each found in the filing text
| Net Sales · FY2025 | $129M | +30% y/y |
| Net Income (Loss) · FY2025 | $17M | +103% y/y |
| Total Shareholder Return · FY2025 | $132.50 | +20% y/y |
19 Mar 20268-K · 8.01Share repurchase authorization $20M; Shares repurchased to date $3Mopen
Figures in the filing · each found in the filing text
| Share repurchase authorization | $20M | |
| Shares repurchased to date | $3M |
4 Mar 20268-K · 2.02, 7.01Net Sales $129M (+30% y/y); Gross Margin 64.3; Net Income $17M (+103% y/y); Guidance: FY2026 net sales growth 10-15%earningsopen
Figures in the filing · each found in the filing text
| Net Sales · FY2025 | $129M | +30% y/y |
| Gross Margin · FY2025 | 64.3% | |
| Net Income · FY2025 | $17M | +103% y/y |
| Adjusted EBITDA · FY2025 | $20M | +139% y/y |
| Basic EPS · FY2025 | $0.22 | +100% y/y |
| Diluted EPS · FY2025 | $0.20 | +82% y/y |
| Operating Cash Flow · FY2025 | $14M | |
| Cash and Cash Equivalents · FY2025 | $65M | |
| Tru Niagen Sales · Tru Niagen · FY2025 | $98M | +27% y/y |
| Niagen Ingredient Sales · Niagen Ingredient · FY2025 | $28M | +45% y/y |
Guidance
FY2026 net sales growth 10-15%
Guidance implies continued growth albeit at a slower pace than FY2025; margin expansion expected.
Risks flagged
Dependence on Tru Niagen brand; competition and regulatory risks in nutraceutical space.
“Tru Niagen sales represent 75% of total net sales.”
4 Mar 202610-KEmployees 117; Inventories $20M (+122% y/y); Net Working Capital $19M (+131% y/y)open
Figures in the filing · each found in the filing text
| Employees · 2025-12-31 | 117 | |
| Inventories · 2025-12-31 | $20M | +122% y/y |
| Net Working Capital · 2025-12-31 | $19M | +131% y/y |
| Research and Development Expense · FY2025 | $6M | +5% y/y |
| Sales and Marketing Expense · FY2025 | $36M | +20% y/y |
| Share-based Compensation Expense · FY2025 | $6M | +66% y/y |
| Intangible Assets, Net · 2025-12-31 | $6M | +1476% y/y |
| Deferred Revenue · 2025-12-31 | $3M | +4% y/y |
Risks flagged
Single supplier dependency for NRC
“We rely on a single manufacturer for the supply of food-grade NRC.” · word for word
Regulatory and compliance risk
“Our operations are subject to regulation by various U.S. federal agencies and similar state and international agencies, including, but not limited to, the FDA, the FTC...” · word for word
Intellectual property expiration
“Key patents expire between 2026 and 2041; some licensed patents expire as early as 2026.”
26 Feb 20268-K · 7.01, 8.01Issued a Regulation FD disclosure (forward guidance or material update); disclosed a material event under other events (litigation, recall, contract loss, or major announcement)open
Risks flagged
Transition services agreement exposes company to operational risks for up to six months post-closing.
“the parties also entered into a transition services agreement pursuant to which the Sellers will provide certain operational and administrative services to the Buyer for a period of up to six months following the closing” · word for word
Focus on NAD+ science and longevity market may concentrate risk in a single therapeutic area.
“focuses resources on NAD+ science, intellectual property, and commercial growth within the longevity industry” · word for word
22 Dec 20258-K · 1.01, 7.01One-time payment $1M; Annual payment 500,000; Annual payment (GBP) 35,000open
Figures in the filing · each found in the filing text
| One-time payment · 2025 | $1M | |
| Annual payment · 2026-2038 | $500000.00 | |
| Annual payment (GBP) · 2026-2038 | $35000.00 | |
| One-time payment 2035 · 2035 | $2M | |
| One-time payment 2038 · 2038 | $2M |
Risks flagged
Future payment obligations may strain cash flow if revenue does not materialize as expected.
“Annual payments of $500,000 and £35,000 through 2038, plus larger payments in 2035 and 2038.” · word for word
4 Nov 202510-QNAGE reported strong Q3 2025 results with net sales up 33% YoY and net income up 144% YoY, driven by consumer products growth.earningsopen
Figures in the filing · each found in the filing text
| Net sales · Consolidated · Q3-2025 | $34M | +33% y/y |
| Net income · Consolidated · Q3-2025 | $5M | +144% y/y |
| Consumer Products net sales · Consumer Products · Q3-2025 | $26M | +44% y/y |
| Ingredients net sales · Ingredients · Q3-2025 | $7M | +8% y/y |
| Analytical reference standards and services net sales · Analytical reference standards and services · Q3-2025 | $772000.00 | -2% y/y |
| Cash and cash equivalents · Consolidated · Q3-2025 | $64M | |
| Inventories · Consolidated · 2026-09-30 | $34M |
Risks flagged
Single supplier dependency for key raw material
“We rely on a single supplier, W.R. Grace, for NRC and a limited number of third-party suppliers for the raw materials required to produce our products.” · word for word
Minimum purchase commitment creates inventory risk
“We have submitted our rolling forecast pursuant to the Grace Supply Agreement, which requires the purchase of approximately $33.6 million in inventory through September 30, 2026.” · word for word
History of operating losses and accumulated deficit
“We have a history of operating losses, may need additional financing to meet our future long-term capital requirements and may be unable to raise sufficient capital on favorable terms or at all.” · word for word
4 Nov 20258-K · 2.02, 7.01Net sales $34M (+33% y/y); Tru Niagen sales $26M (+44% y/y); Gross margin 64.5; Guidance: Full year 2025 net sales growth raised to 25-30% from 22-27%earningsopen
Figures in the filing · each found in the filing text
| Net sales · Q3-2025 | $34M | +33% y/y |
| Tru Niagen sales · Tru Niagen · Q3-2025 | $26M | +44% y/y |
| Gross margin · Q3-2025 | 64.5% | |
| Net income · Q3-2025 | $5M | +142% y/y |
| Adjusted EBITDA · Q3-2025 | $6M | +120% y/y |
| Sales and marketing expense as % of net sales · Q3-2025 | 25.8% | |
| Cash provided by operations · 9M-2025 | $13M | +266% y/y |
| Cash · Q3-2025 | $64M |
Guidance
Full year 2025 net sales growth raised to 25-30% from 22-27%
Raised full year guidance with net sales growth expected between 25% to 30%, driven by strong momentum.
Risks flagged
Dependence on e-commerce channel and B2B partnerships for growth.
“Growth in net sales was primarily driven by growth in Tru Niagen® sales, supported by strong e-commerce channel performance.” · word for word
Niagen Bioscience, Inc. — questions
- What did Niagen Bioscience, Inc. file recently?
- 13 SEC filings in the last 12 months. Latest: 10-Q on 2026-08-04 — Niagen Bioscience reported Q2 2026 net sales of $29.8M (-4% YoY) and net income of $1.0M (-73% YoY), with consumer product growth offset by ingredient sales decline due to NMN competition and margin pressure.
Every figure on this page comes from Niagen Bioscience, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.